STOCK TITAN

Edwards Lifesciences signs $750M revolving credit deal

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Edwards Lifesciences Corp. (EW) amended and restated its existing bank facility through a five-year, $750 million multi-currency unsecured revolving credit facility that matures November 19, 2031. The company said the agreement has improved terms and an extended maturity compared with its 2022 agreement. No amounts had been borrowed under the new facility.

U.S. dollar borrowings may bear a variable rate based on the Secured Overnight Financing Rate or a base rate, at the company’s election, plus a margin tied to its leverage ratio or debt ratings. The agreement permits an increase of up to $375 million, subject to its terms and lender agreement. Covenants include a maximum leverage ratio, and a default could cause obligations to become due and the facility to be terminated.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Financial
The company incurred a new significant debt or off-balance-sheet obligation.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Revolving credit facility $750 million Five-year multi-currency unsecured facility
Potential facility increase Up to an additional $375 million Subject to certain terms and conditions and lender agreement
Facility term Five years Amended and restated credit agreement
Maturity date November 19, 2031 Credit Agreement
multi-currency unsecured revolving credit facility financial
"provides for a five-year $750 million multi-currency unsecured revolving credit facility"
Secured Overnight Financing Rate financial
"variable rate based on the Secured Overnight Financing Rate"
A secured overnight financing rate (SOFR) is a daily benchmark interest rate that reflects the cost of borrowing cash overnight using U.S. Treasury securities as collateral. Think of it as the market price to “rent” cash for a day with a very safe pledge, similar to paying a short-term rental fee for money backed by government bonds. Investors track SOFR because it underpins pricing for loans, bonds and derivatives, so movements change borrowing costs, interest income and the valuation of interest-rate–linked positions.
applicable margin financial
"plus, in each case, an applicable margin based on the Company’s leverage ratio or debt ratings"
Applicable margin is the extra percentage added to a base interest rate to calculate the actual interest a borrower pays on a floating-rate loan or credit line. Investors care because it directly affects a company’s borrowing cost—higher margins raise interest expense and reduce profit and cash flow, while lower margins make financing cheaper; think of it as a variable surcharge on a sale price that reflects the lender’s view of risk.
maximum leverage ratio financial
"The Company must also comply with a maximum leverage ratio"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How large is EW’s new revolving credit facility and when does it mature?

Edwards Lifesciences and certain subsidiaries entered into a $750 million revolving credit facility for five years. The multi-currency unsecured facility matures November 19, 2031.

Can EW increase the amount available under its credit agreement?

Yes. Edwards may increase the amount available by up to an additional $375 million in the aggregate, subject to certain terms and conditions and the agreement of the lenders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001099800false00010998002026-11-192026-11-19


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported) November 19, 2026
 
EDWARDS LIFESCIENCES CORPORATION
(Exact name of registrant as specified in its charter)
Delaware1-1552536-4316614
(State or other jurisdiction
of incorporation)
(Commission
file number)
(IRS Employer
Identification No.)

One Edwards Way
Irvine, California 92614
investor_relations@edwards.com
(Address of principal executive offices and zip code)

(949) 250-2500
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $1.00 per shareEWNew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 1.01.                                   Entry into a Material Definitive Agreement.

As part of a planned refreshment of its bank credit facility, on November 19, 2026, Edwards Lifesciences Corporation (the “Company”) entered into an Amended and Restated Five Year Credit Agreement, dated as of November 19, 2026, among the Company and certain of its subsidiaries, as Borrowers, the lenders signatory thereto and Bank of America, N.A., as Administrative Agent (the “Credit Agreement”). The Credit Agreement, which is further described in Item 2.03 below, amends and restates the Company’s existing Five Year Credit Agreement, dated as of July 15, 2022, by and among the Company, certain of its subsidiaries, the lenders signatory thereto and Bank of America, N.A., as Administrative Agent (the “2022 Credit Agreement”), and features improved terms and an extended maturity date compared to the 2022 Credit Agreement.

Item 2.03.                                    Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
 
On November 19, 2026, the Company entered into the Credit Agreement, which amends and restates the 2022 Credit Agreement and provides for a five-year $750 million multi-currency unsecured revolving credit facility. All committed pro rata United States dollar-denominated borrowings under the Revolving Facility will bear interest at a variable rate based on the Secured Overnight Financing Rate as administered by the Federal Reserve Bank of New York or base rate, at the Company’s election, subject to the terms and conditions thereof, plus, in each case, an applicable margin based on the Company’s leverage ratio or debt ratings. Subject to certain terms and conditions and the agreement of the lenders, the Company may increase the amount available under the Credit Agreement by up to an additional $375 million in the aggregate. The Credit Agreement matures November 19, 2031.

The Credit Agreement contains customary representations, warranties, covenants, events of default, terms and conditions, including limitations on liens, incurrence of debt, mergers and significant asset dispositions. The Company must also comply with a maximum leverage ratio. The occurrence of an event of default under the Credit Agreement could result in all loans and other obligations being declared due and payable and the Credit Agreement being terminated.

The Company expects to use any borrowings under the Credit Agreement for general corporate purposes. As of the date of this Current Report on Form 8-K, no amounts have been borrowed under the Credit Agreement.

The Company and its affiliates from time to time engage certain of the lenders under the Credit Agreement to provide banking and financial services. All of these engagements are negotiated at arm’s length.

The foregoing description of the Credit Agreement is qualified in its entirety by reference to the complete terms and conditions of the Credit Agreement, a copy of which is filed herewith as Exhibit 10.1 and incorporated herein by reference.

Item 9.01.                                      Financial Statements and Exhibits.
 
(d)Exhibits
10.1
Amended and Restated Five Year Credit Agreement, dated as of November 19, 2026, among Edwards Lifesciences Corporation and certain of its subsidiaries, as Borrowers, the lenders signatory thereto and Bank of America, N.A., as Administrative Agent.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).

2


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Date: November 19, 2026
EDWARDS LIFESCIENCES CORPORATION
By:/s/ Theodora Mistras
Theodora Mistras
Chief Financial Officer

3

Filing Exhibits & Attachments

4 documents

Keep reading